

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of applying a drug-polymer coating on a stent, comprising:

dipping a stent framework into a first polymeric solution, wherein the first polymeric solution comprises a first polymer, a first therapeutic agent, and a first solvent, wherein the first polymer comprises a copolymer of methacrylamide, methacrylate and vinyl alcohol, the first therapeutic agent comprises 5-fluorouracil, and the first solvent comprises a mixture of chloroform and water;

drying the first polymeric solution to form a thin drug-polymer layer on the stent framework;

dipping the stent framework including the thin drug-polymer layer into a second polymeric solution, wherein the second polymeric solution comprises a second polymer and a second solvent, [[and]] wherein the thin drug-polymer layer is insoluble in the second polymeric solution, and wherein the second polymer comprises a rigid thermoplastic polyurethane and the second solvent comprises tetrahydrofuran;

drying the second polymeric solution to form a thin barrier layer on the first thin drug-polymer layer; and

repeating the steps of dipping the stent framework into the first polymeric solution, drying the first polymeric solution, dipping the stent framework into the second polymeric solution, and drying the second polymeric solution until a target drug-polymer coating thickness is disposed on the stent framework.

Claim 2 (cancelled).

Claim 3 (original): The method of claim 1 wherein the first polymeric solution comprises between 0.05 percent and 10.0 percent total solids by weight of the first polymer.

Claims 4-16 (cancelled).

Claim 17 (currently amended): The method of ~~claim 16~~ claim 1 wherein the second polymeric solution comprises an anti-inflammatant.

Claim 18 (currently amended): The method of ~~claim 16~~ claim 1 wherein the second polymeric solution comprises dexamethasone.

Claim 19 (currently amended): A [[The]] method of ~~claim 1~~ applying a drug-polymer coating on a stent, comprising:

dipping a stent framework into a first polymeric solution, wherein the first polymeric solution comprises a first polymer, a first therapeutic agent, and a first solvent, wherein the first polymer comprises a copolymer of methacrylamide, methacrylate and vinyl acetate; the first therapeutic agent comprises dexamethasone; and the first solvent comprises ethanol;

drying the first polymeric solution to form a thin drug-polymer layer on the stent framework;

dipping the stent framework including the thin drug-polymer layer into a second polymeric solution, wherein the second polymeric solution comprises a second polymer and a second solvent, wherein the second polymer comprises poly(butyl methacrylate); and the second solvent comprises a blend of tetrahydrofuran and methanol, and wherein the thin drug-polymer layer is insoluble in the second polymeric solution;

drying the second polymeric solution to form a thin barrier layer on the first thin drug-polymer layer; and

repeating the steps of dipping the stent framework into the first polymeric solution, drying the first polymeric solution, dipping the stent framework into the second polymeric solution, and drying the second polymeric solution until a target drug-polymer coating thickness is disposed on the stent framework.

Claim 20 (original): The method of claim 19 wherein the second polymeric solution comprises an anti-proliferative compound.

Claim 21 (original): The method of claim 19 wherein the second polymeric solution comprises 5-fluorouracil.

Claim 22 (original): The method of claim 1 wherein the thin barrier layer is insoluble in the first polymeric solution.

Claim 23 (original): The method of claim 1 wherein drying the first polymeric solution comprises positioning the dipped stent framework in air after dipping the stent framework into the first polymeric solution, and evaporating the first solvent.

Claim 24 (original): The method of claim 1 wherein drying the second polymeric solution comprises positioning the dipped stent framework in air after dipping the stent framework into the second polymeric solution, and evaporating the second solvent

Claim 25 (original): The method of claim 1 further comprising:
modulating a concentration of the first therapeutic agent in the thin drug-polymer layers to provide a predetermined drug-release profile.

Claims 26-62 (cancelled).